JP2024532426A - エイズウイルス感染の遺伝子治療用の遺伝子配列構築体 - Google Patents

エイズウイルス感染の遺伝子治療用の遺伝子配列構築体 Download PDF

Info

Publication number
JP2024532426A
JP2024532426A JP2024513388A JP2024513388A JP2024532426A JP 2024532426 A JP2024532426 A JP 2024532426A JP 2024513388 A JP2024513388 A JP 2024513388A JP 2024513388 A JP2024513388 A JP 2024513388A JP 2024532426 A JP2024532426 A JP 2024532426A
Authority
JP
Japan
Prior art keywords
gene
hiv infection
hiv
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532426A5 (cg-RX-API-DMAC7.html
Inventor
ウ,ハオチュァン
スン,バオチェン
ダン,イン
Original Assignee
カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド filed Critical カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド
Publication of JP2024532426A publication Critical patent/JP2024532426A/ja
Publication of JP2024532426A5 publication Critical patent/JP2024532426A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024513388A 2021-08-30 2022-08-30 エイズウイルス感染の遺伝子治療用の遺伝子配列構築体 Pending JP2024532426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/115420 2021-08-30
CN2021115420 2021-08-30
PCT/CN2022/115822 WO2023030312A1 (zh) 2021-08-30 2022-08-30 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Publications (2)

Publication Number Publication Date
JP2024532426A true JP2024532426A (ja) 2024-09-05
JP2024532426A5 JP2024532426A5 (cg-RX-API-DMAC7.html) 2025-09-09

Family

ID=85410863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513388A Pending JP2024532426A (ja) 2021-08-30 2022-08-30 エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Country Status (7)

Country Link
US (1) US20240391981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4397748A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532426A (cg-RX-API-DMAC7.html)
CN (1) CN117980465A (cg-RX-API-DMAC7.html)
AU (1) AU2022338817A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230492A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023030312A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532453A (ja) * 2021-08-30 2024-09-05 カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114645066B (zh) * 2020-12-21 2023-08-25 康霖生物科技(杭州)有限公司 一种用于艾滋病基因治疗的核酸构建体
EP4408892A4 (en) * 2021-09-29 2025-11-19 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500984A (ja) * 2006-08-17 2010-01-14 エフ.ホフマン−ラ ロシュ アーゲー Ccr5に対する抗体と抗膜融合ペプチドとの抱合体
JP2010534212A (ja) * 2007-07-20 2010-11-04 エフ.ホフマン−ラ ロシュ アーゲー 抗cd4抗体と抗膜融合性ペプチドとのコンジュゲート
JP2021506306A (ja) * 2017-12-20 2021-02-22 レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. 免疫療法を用いてhiv/aidsを処置するための組成物および方法
JP2024532453A (ja) * 2021-08-30 2024-09-05 カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957838C2 (de) * 1999-11-25 2002-11-21 Pette Heinrich Inst Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
CN101500615A (zh) * 2006-08-17 2009-08-05 霍夫曼-拉罗奇有限公司 针对ccr5的抗体和抗融合肽的缀合物
AU2013251184A1 (en) * 2007-07-20 2013-11-14 F.Hoffmann-La Roche Ag A conjugate of an antibody against CD4 and antifusogenic peptides
CA2794632A1 (en) * 2010-05-03 2011-11-10 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv entry
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
WO2016171980A1 (en) * 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides targeting hiv fusion
CN108727475B (zh) * 2017-04-18 2020-08-25 中国医学科学院病原生物学研究所 强效抑制hiv的脂肽、其衍生物、其药物组合物及其用途
CN111819196B (zh) * 2017-12-21 2022-10-28 纽约市哥伦比亚大学理事会 双特异性hiv-1中和抗体
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
CN114645066B (zh) * 2020-12-21 2023-08-25 康霖生物科技(杭州)有限公司 一种用于艾滋病基因治疗的核酸构建体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500984A (ja) * 2006-08-17 2010-01-14 エフ.ホフマン−ラ ロシュ アーゲー Ccr5に対する抗体と抗膜融合ペプチドとの抱合体
JP2010534212A (ja) * 2007-07-20 2010-11-04 エフ.ホフマン−ラ ロシュ アーゲー 抗cd4抗体と抗膜融合性ペプチドとのコンジュゲート
JP2021506306A (ja) * 2017-12-20 2021-02-22 レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. 免疫療法を用いてhiv/aidsを処置するための組成物および方法
JP2024532453A (ja) * 2021-08-30 2024-09-05 カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FALKENHAGEN A. ET AL.: "A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection", GENE THERAPY, vol. 21, JPN6026031260, 2014, pages 175 - 187, ISSN: 0005918238 *
JEKLE A. ET AL.: "CD4-BFFI: A novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency", ANTIVIRAL RESEARCH, vol. 83, JPN6026031262, 2009, pages 257 - 266, ISSN: 0005918239 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532453A (ja) * 2021-08-30 2024-09-05 カンリン バイオテクノロジー(ハンチョウ)カンパニー リミテッド エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Also Published As

Publication number Publication date
EP4397748A1 (en) 2024-07-10
US20240391981A1 (en) 2024-11-28
EP4397748A4 (en) 2025-09-17
CN117980465A (zh) 2024-05-03
CA3230492A1 (en) 2023-03-09
AU2022338817A1 (en) 2024-03-07
WO2023030312A1 (zh) 2023-03-09

Similar Documents

Publication Publication Date Title
US11192941B2 (en) Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
Saunders et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection
US7939083B2 (en) Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
US20240391981A1 (en) Gene sequence construct for gene therapy for hiv infection
JP3855071B2 (ja) 抗hivモノクローナル抗体
Padte et al. Engineering multi-specific antibodies against HIV-1
US20240352096A1 (en) Gene sequence construct for gene therapy of human immunodeficiency virus infection
WO2021213421A1 (zh) 融合蛋白分子及其制备方法和用途
WO2022135139A1 (zh) 一种用于艾滋病基因治疗的核酸构建体
US12209113B2 (en) Methods and compositions for protection against lentiviral infections
WO2018057916A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
CA2481813A1 (en) Antibody gene transfer and recombinant aav therefor
US20240285790A1 (en) Antibody-cd4 conjugates and methods of using the same
JP2024532453A5 (cg-RX-API-DMAC7.html)
JP2024532426A5 (cg-RX-API-DMAC7.html)
CN116284419A (zh) 靶向人gucy2c蛋白的单克隆抗体及其应用
Schnepp et al. Vector-mediated antibody gene transfer for infectious diseases
US7488481B2 (en) Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5
US20230348597A1 (en) Sars-cov-2 therapies
US20260139037A1 (en) Compositions and methods for hiv latency reversal
WO2025229019A1 (en) Neutralizing antibody constructs against hiv
CN121021695A (zh) 靶向PDGFRβ的单链抗体及其在CAR-T免疫治疗中的应用
CN121021697A (zh) 靶向人PDGFRβ的scFV抗体及其在清除产细胞外基质细胞的抗纤维化免疫治疗中的应用
Couto Synthetic antibodies targeting HIV-1 infectivity
Moodie Sequential Adeno-Associated Virus Delivered HIV-1 Subtype C Env Glycoproteins as Novel Vaccine Immunogens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260728